Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy.
Azienda Ospedaliero-Universitaria Careggi, Radiation Oncology Unit, Florence, Italy.
Cancer Treat Res Commun. 2021;26:100263. doi: 10.1016/j.ctarc.2020.100263. Epub 2020 Dec 10.
GBM (glioblastoma multiforme) is the most common and aggressive brain tumor. To date, treatment options for glioblastoma recurrence are lacking. Recently, REGOMA trial showed the superiority of regorafenib to lomustine in patients with first glioblastoma recurrence. We report an excellent response to three months treatment with regorafenib, in a patient who presented a rapid progression after the end of post operative radio-chemotherapy and after only one cycle of adjuvant TMZ (Temozolomide).
GBM（多形性胶质母细胞瘤）是最常见和最具侵袭性的脑肿瘤。迄今为止，胶质母细胞瘤复发的治疗选择有限。最近，REGOMA 试验显示regorafenib 在首次胶质母细胞瘤复发患者中的疗效优于洛莫司汀。我们报告了一例患者在术后放化疗结束后和仅接受一个周期辅助 TMZ（替莫唑胺）治疗后快速进展后，用regorafenib 治疗三个月的极佳反应。
